Mefenamic acid
مفنامیک اسید
🦴 Musculo-Skeletal SystemNSAID
Market / country: 🇺🇸 USA
Ponstel (US)
🧮 Dose calculator
Mild to moderate pain · Regimen source: FDA Mefenamic acid · 2.2FDA Mefenamic acid · 1.1
- • 500 mg initial dose, then 250 mg every 6 hours as needed; not more than one week. FDA Mefenamic acid · 2.2FDA Mefenamic acid · 1.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⚠️ Safety and effectiveness for pain not established under 14 years. FDA Mefenamic acid · 8.4
- ⛔ Hypersensitivity to mefenamic acid; asthma, urticaria or allergic reactions after aspirin/NSAIDs; CABG surgery. FDA Mefenamic acid · 4
Formulations
- 250 mg capsule — capsule 🇺🇸 USA FDA Mefenamic acid · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Mefenamic acid · 8.1
“Clinical Considerations Fetal/Neonatal Adverse Reactions Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy, because NSAIDs, including mefenamic acid capsules, can cause premature closure of the fetal ductus arteriosus (see Data) .”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Mefenamic acid · 8.2
“Risk Summary Mefenamic acid is present in human milk in low amounts and may be transferred to breastfed infants.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Mefenamic acid · 8.4
“The safety and effectiveness of mefenamic acid have been established for management of mild to moderate pain in pediatric patients 14 years of age and older.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Mefenamic acid · Boxed Warning
“Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions ( 5.2 )].”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Mefenamic acid · 8.9
“Infertility Females Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including mefenamic acid may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.”
🔗 Reference links
- FDA (approval record)ANDA091322
- DailyMed (FDA label)FDA Mefenamic acid
- MedlinePlus (NIH)Mefenamic Acid
- WHO ATC/DDDM01AG01
- Darooyab (Iran)Mefenamic-Acid
🇮🇷 Registered in Iran Darooyab · G-124/Mefenamic-Acid
Dosage forms with Iranian generic codes, per Darooyab.
- 00794 · MEFENAMIC ACID 250MG CAP · کپسول مفنامیک اسید ۲۵۰ میلیگرم
- 53049 · MEFENAMIC ACID 500MG CAP · کپسول مفنامیک اسید ۵۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Mefenamic acid · 3FDA Mefenamic acid · 2.2FDA Mefenamic acid · 1.1FDA Mefenamic acid · 2.3FDA Mefenamic acid · 8.4FDA Mefenamic acid · 4FDA Mefenamic acid · 8.1FDA Mefenamic acid · 8.2FDA Mefenamic acid · Boxed WarningFDA Mefenamic acid · 8.9FDA Mefenamic acid · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-124/Mefenamic-Acid
- Clinical review⚠ Unverified